Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis

NCT02874066 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT02874066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02874066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Lead sponsor
National Taiwan University Hospital
Phase
Phase 4
Overall status
Completed
Start date
March 13, 2017
Completion date
December 25, 2018
Enrollment
46 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis viruses